SecBot SecBot

AURA

Aura Biosciences, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001501796 Biotech & Drug Discovery
$6.18 −0.12 (−1.90%)
Oct 26 4:00 PM ET · prev $6.30
Market cap
$669.9M
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$15.00
+143% · range $12.00–23.00
Next earnings
Nov 5
in 9 days · EPS est. −$0.37
1 year
+1.3%
from $6.10 · Oct 27
30 days
+0.5%
from $6.15
52-week range
$4.97–8.90
−31% from high · low Jan 20
Avg volume 20D
942.3K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$39.7M
0 buyers · 7 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 3 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 5, 2026
Strongest BEARISH Aura Biosciences reported Q2 2026 EPS of -$0.48, a 33.3% miss vs consensus of -$0.38, with revenue of $0…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $39.7M.

  • InstitutionsBULLISH

    Q2 2026: 27 added (1 new), 13 trimmed or exited. Largest new: Ra Capital Management, $17.8M.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.367 → −$0.367 over 90 days. 1 up, 3 down in 30 days.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$17.8M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD4,707,674$33.4M
VANGUARD CAPITAL MANAGEMENT LLCADD4,100,342$29.1M
RA CAPITAL MANAGEMENT, L.P.NEW2,500,000$17.8M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED2,354,619$16.7M
GEODE CAPITAL MANAGEMENT, LLCADD1,754,721$12.5M
STATE STREET CORPADD1,222,984$8.7M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED871,342$6.2M
VANGUARD FIDUCIARY TRUST COADD637,204$4.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +143%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$39.7M
sold · 7 insiders
DateInsiderTypeValue
Sep 1, 2026
Kratz Erica
Chief Reg. & Quality Officer
AWARD199,115 sh
Sep 1, 2026
Hopkins Janet Jill
Chief Medical Officer
AWARD58,850 sh
Sep 1, 2026
Abu-Absi Susan
Chief Operating Officer
AWARD265,487 sh
Sep 1, 2026
Abu-Absi Susan
Chief Operating Officer
AWARD134,513 sh
Sep 1, 2026
Elazzouzi Amy
SVP, Finance & PAO
AWARD23,540 sh
Sep 1, 2026
Person Julie
Chief People Officer
AWARD212,389 sh
Sep 1, 2026
Kratz Erica
Chief Reg. & Quality Officer
AWARD100,885 sh
Sep 1, 2026
Hopkins Janet Jill
Chief Medical Officer
AWARD116,150 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.37
EPS estimate, this quarter
0%
estimate change, 90 days
1↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.37-$0.41–-$0.32+0.0%$0.00
Next Q-$0.35-$0.39–-$0.27+7.9%$0.00
Current FY-$1.67-$1.78–-$1.50-4.4%$0.00
Next FY-$1.52-$1.70–-$1.15+9.0%$4.9M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Short interest report
Short Interest: AURA up 47% to 10.4M shares
Settlement 2026-09-30 | Days to cover: 9.23 | ≈10.00% of shares outstanding (est.)
Sep 22, 2026 SEC
A cluster of 25 institutional buyers added $29.4M in AURA positions during Q2 2026, led by Vanguard (+$19.5M) and…
INST-CLUSTER — Impact 3/10
Sep 1, 2026 Insider
Kratz Erica was granted 199,115 shares
Chief Reg. & Quality Officer
Sep 1, 2026 Insider
Hopkins Janet Jill was granted 58,850 shares
Chief Medical Officer
Sep 1, 2026 Insider
Abu-Absi Susan was granted 265,487 shares
Chief Operating Officer
Aug 21, 2026 SEC
Aura Biosciences' S-3 shelf registration (File No. 333-298228) became effective on August 20, 2026, allowing the…
EFFECT — Impact 4/10
Aug 11, 2026 SEC
Aura Biosciences reported Q2 2026 EPS of -$0.48, a 33.3% miss vs consensus of -$0.38, with revenue of $0. The net loss…
PRESS-RELEASE — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
4,707,674 shares ($33.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
AURA Q3 2026 Earnings Before Market Open — 2026-11-05
Recent
Sep 30, 2026
Short interest
Short Interest: AURA up 47% to 10.4M shares
Settlement 2026-09-30 | Days to cover: 9.23 | ≈10.00% of shares outstanding (est.)
Aug 11, 2026
Earnings
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027
Aug 6, 2026
Earnings date
AURA Q2 2026 Earnings Before Market Open — 2026-08-06
Jul 8, 2026
Press release
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision…
Jun 30, 2026
Short interest
Short Interest: AURA up 29% to 6.9M shares
Settlement 2026-06-30 | Days to cover: 9.34 | ≈6.70% of shares outstanding (est.)

SecBot reports

10 filings · 6 press releases · 1 bullish · 5 bearish · 4 neutral
All AURA filing & press-release reports (16)